Emily Bodnar’s ranking relies over the anticipation of significant milestones for Agenus in the coming 12 months, significantly the possible submitting of a Biologics License Software (BLA) for their guide drug prospect, botensilimab (bot). Agenus has dosed about 900 individuals with bot across several stable tumors, demonstrating a determination